Pfizer Advances PF-08653944 Liver Study, Reinforcing Long-Term Pipeline Visibility

Pfizer Inc (PFE) announced an update on their ongoing clinical study.

Pfizer Inc. (PFE) has launched a Phase 1 study titled “A PHASE 1, OPEN-LABEL, SINGLE-DOSE, PARALLEL-GROUP STUDY TO EVALUATE THE PHARMACOKINETICS, SAFETY AND TOLERABILITY OF PF-08653944 IN ADULTS WITH AND WITHOUT VARYING DEGREES OF HEPATIC IMPAIRMENT.” The goal is to see how this new drug behaves in the body and how safe it is in adults with normal and reduced liver function.

The treatment being tested is PF-08653944, also called MET097, given as a one-time injection under the skin. It is an experimental drug and this early work aims to support future use in people who may also have liver disease.

The trial is interventional and uses a parallel-group design, meaning different groups are treated at the same time. There is no randomization or blinding, and the main purpose is basic research on how the drug moves through the body and how well it is tolerated.

Participants are split into four groups: adults with normal liver function and those with mild, moderate, or severe liver problems. All receive a single dose and then return for blood tests and safety checks so doctors can compare results across these groups.

The study started on April 2, 2026, which marks the first date participants could enroll. The latest update on April 20, 2026 signals that the protocol and status have been recently reviewed and the trial remains active.

Key completion dates, including primary and final completion, have not yet been reported, highlighting that this is still an early-stage program. As results are posted, investors will get clearer signals about dose, safety margins, and how liver function may constrain or enable broader use.

For markets, this update reinforces Pfizer’s push to expand its pipeline with targeted, data-driven programs, even at small early scale. A clean safety and drug-handling profile could support future combination or specialty indications, which may matter more over the long term than as an immediate stock catalyst.

Competitors in liver and specialty metabolic drugs, including large pharma peers, are also investing in early hepatic safety work, so this study keeps Pfizer aligned with industry best practice. Investor sentiment is likely to be neutral near term, but steady pipeline progress helps support confidence in PFE’s R&D strategy.

The study is currently recruiting and remains active, with more detailed information and ongoing updates available on the ClinicalTrials.gov portal under identifier NCT07519135.

To learn more about PFE’s potential, visit the Pfizer Inc drug pipeline page.